Chen Schor

Chen Schor

President and Chief Executive OfficeratAdicet Bio· In proxies 2022–2025

Pay in FY2023+50% from the year before · Adicet Bio stock -78.9% the same year

Chen Schor was paid $6.0M in FY2023 (Dec), up 50%. Adicet Bio stock fell 78.9% that year.

Pay$100 in the stock at the end of FY21 → $11
Pay is from the Summary Compensation Table of each Adicet Bio proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Adicet BioPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -98%
  2. KaryopharmPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  3. Karyopharm Therapeutics Inc.Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  4. Alliance for Cancer Gene TherapyPublic company
    • Director? – PresentNo stock prices for these years
  5. Carbon Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Brainstorm Cell Therapeutics Inc.Public company · 9 yr
    • Director2011 – 2020 · 9 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?